One of my first posts about HDAC inhibitors was back in 2016: HDAC (Histone deacetylase) inhibitors for melanoma
Noting that researchers had hopes that in melanoma they could be used to try to overcome resistance to BRAF inhibitors, though at that time...not too much had come of them.
At ASCO this year, there was this: ASCO 2017: Pembro plus Entinostat (histone deacetylase inhibitor - HDAC)
Where as the abstract discussed combining Pembro (now Keytruda) with entinostat, I noted: "Existing evidence supports the hypothesis that HDAC inhibitors (HDACi) may sensitize melanoma cells to immunotherapy and targeted therapy and hence bear therapeutic potential concurrent with immune checkpoint blockade or BRAF and MEK inhibition."
Now, there's this: